Whether low-dose metronomic oral cyclophosphamide improves the response to docetaxel in first-line treatment of non-triple-negative metastatic breast cancer.

Oncotarget · 2017 · PMC5668065 · PMID 29108332

Europe PMC DOI

hedged sentence

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

marginally significantP = 0.09so close (0.05 < p ≤ 0.1)

Last, our study demonstrated a non-statistically but marginally significant improvement in term of ORR (71.4% vs. 51.6%; P = 0.09) or PFS (18.5 vs. 11.7 months; P = 0.07) with the addition of metronomic oral cyclophosphamide.

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.